Delta hepatitis epidemiology and the global burden of disease.
HDV
delta hepatitis
epidemiology
prevalence
risk factors
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
30
10
2022
accepted:
25
11
2022
medline:
20
4
2023
pubmed:
11
1
2023
entrez:
10
1
2023
Statut:
ppublish
Résumé
Delta Hepatitis is considered the most severe form of hepatitis, with varied prevalence, genotype distribution and risk factors worldwide. Current knowledge of global epidemiology is limited due to variable screening practices for HDV. Here, we summarize what is currently known about the prevalence of testing and prevalence of HDV positivity globally.
Substances chimiques
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4-10Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Brillanti S. Management of delta hepatitis 45 years after the discovery of HDV. J Clin Med. 2022;11(6):1587. doi:10.3390/jcm11061587
Yardeni D, Heller T, Koh C. Chronic hepatitis D-what is changing? J Viral Hepat. 2022;29(4):240-251. doi:10.1111/jvh.13651
Gilman C, Heller T, Koh C. Chronic hepatitis delta: a state-of-the-art review and new therapies. World J Gastroenterol. 2019;25(32):4580-4597. doi:10.3748/wjg.v25.i32.4580
Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74(5):1200-1211. doi:10.1016/j.jhep.2021.01.014
Da BL, Rahman F, Lai WC, Kleiner DE, Heller T, Koh C. Risk factors for delta hepatitis in a north American cohort: who should Be screened? Am J Gastroenterol. 2021;116(1):206-209. doi:10.14309/ajg.0000000000000954
Hayashi T, Takeshita Y, Hutin YJ, et al. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? Arch Public Health. 2021;79:180. doi:10.1186/s13690-021-00693-2
Besombes C, Njouom R, Paireau J, et al. The epidemiology of hepatitis delta virus infection in cameroon. Gut. 2020;69(7):1294-1300. doi:10.1136/gutjnl-2019-320027
Daw MA, Daw AM, Sifennasr NEM, et al. The epidemiology of hepatitis D virus in North Africa: a systematic review and meta-analysis. ScientificWorldJournal. 2018;2018:9312650. doi:10.1155/2018/9312650
Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20(24):7635-7643. doi:10.3748/wjg.v20.i24.7635
Aguilera A, Trastoy R, Barreiro P, et al. Decline and changing profile of hepatitis delta among injection drug users in Spain. Antivir Ther. 2018;23(1):87-90. doi:10.3851/IMP3161
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98. doi:10.1007/s12072-015-9675-4
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis. 2018;12(1):33-34. doi:10.1002/cld.728
Kushner T, Serper M, Kaplan DE. Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586-592. doi:10.1016/j.jhep.2015.04.025
Gish RG, Yi DH, Kane S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in northern California. J Gastroenterol Hepatol. 2013;28(9):1521-1525. doi:10.1111/jgh.12217
Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59(5):949-956. doi:10.1016/j.jhep.2013.07.005
El Bouzidi K, Elamin W, Kranzer K, et al. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. J Clin Virol. 2015;66:33-37. doi:10.1016/j.jcv.2015.02.011
Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523-532. doi:10.1016/j.jhep.2020.04.008
Martinez-Camprecios J, Rando-Segura A, Buti M, et al. Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. J Virol Methods. 2021;289:114039. doi:10.1016/j.jviromet.2020.114039
Palom A, Rando-Segura A, Vico J, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Rep. 2022;4(10):100547. doi:10.1016/j.jhepr.2022.100547
Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512-521. doi:10.1136/gutjnl-2018-316601
Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677-1687. doi:10.1093/infdis/jiz633
Safaie P, Razeghi S, Rouster SD, Privitera I, Sherman KE. Hepatitis D diagnostics: utilization and testing in the United States. Virus Res. 2018;250:114-117. doi:10.1016/j.virusres.2018.03.013
Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202(6):845-852. doi:10.1086/655808
Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011-2016. Clin Infect Dis. 2019;69(4):709-712. doi:10.1093/cid/ciz001
Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep. 2019;7(4):231-245. doi:10.1093/gastro/goz023
Koh C, Heller T, Glenn JS. Pathogenesis of and new therapies for hepatitis D. Gastroenterology. 2019;156(2):461-476.e1. doi:10.1053/j.gastro.2018.09.058
Stockdale AJ, Kreuels B, Henrion MRY, Giorgi E, Kyomuhangi I, Geretti AM. Hepatitis D prevalence: problems with extrapolation to global population estimates. Gut. 2020;69(2):396-397. doi:10.1136/gutjnl-2018-317874
Su CW, Huang YH, Huo TI, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130(6):1625-1635. doi:10.1053/j.gastro.2006.01.035
Lutterkort GL, Wranke A, Hengst J, et al. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. J Viral Hepat. 2018;25(11):1384-1394. doi:10.1111/jvh.12947
Palom A, Rodriguez-Tajes S, Navascues CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Aliment Pharmacol Ther. 2020;51(1):158-166. doi:10.1111/apt.15521
Kushner T, Da BL, Chan A, Dieterich D, Sigel K, Saberi B. Liver transplantation for hepatitis D virus in the United States: a UNOS study on outcomes in the MELD era. Transplant Direct. 2022;8(1):e1253. doi:10.1097/TXD.0000000000001253
Adam R, Karam V, Cailliez V, et al. 2018 annual report of the European liver transplant registry (ELTR) - 50-year evolution of liver transplantation. Transpl Int. 2018;31(12):1293-1317. doi:10.1111/tri.13358
Martini S, Tandoi F, Romagnoli R, Rizzetto M. Liver transplantation in hepatitis B/hepatitis D (Delta) virus coinfected recipients. Transplantation. 2022;106(10):1935-1939. doi:10.1097/TP.0000000000004138
Buti M, Stepanova M, Palom A, et al. Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. JHEP Rep. 2021;3(3):100280. doi:10.1016/j.jhepr.2021.100280